Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China
BMJ Open. 2021 Jun 28;11(6):e047543. doi: 10.1136/bmjopen-2020-047543.
Ulcerative colitis (UC) is a type of inflammatory bowel disease, and 62% of patients with UC felt that it is difficult for them to live a normal life. Furthermore, some researches have shown that about 15% of patients with UC undergo at least one extreme clinical course in their lifetime, and 10%-30% of patients with UC oblige colectomy. Although many investigations have demonstrated that HBO has a beneficial impact on UC treatment, a systematic review and meta-analysis are unavailable. Therefore, a meta-analysis is essential to assess the efficacy and safety of HBO in treating UC.
A systematic search plan will be performed in the following seven databases with a restriction of time from inception to September 2020 to filter the eligible studies: PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure, Chinese Scientific Journal Database (VIP) and Chinese Biomedical Database WanFang. Other related resources will be also searched. Two independent reviewers will choose eligible researches and extract data. The risk of bias will be evaluated based on Cochrane Collaboration's Risk of Bias tool and Newcastle-Ottawa Scale. Eventually, a systematic review and meta-analysis will be performed via the Review Manager V.5.3 statistical software and STATA V.14.0 software.
This study will not involve the individual patient and any ethical problems since its outcomes are based on published data. Therefore, no ethical review and approval are required. We plan to publish the study in a peer-reviewed journal.
CRD42020210244.
溃疡性结肠炎（UC）是一种炎症性肠病，62%的 UC 患者认为他们难以过上正常生活。此外，一些研究表明，UC 患者中有约 15%在其一生中至少经历过一次极端临床病程，10%-30%的 UC 患者需要进行结肠切除术。尽管许多研究表明高压氧（HBO）对 UC 治疗有有益影响，但目前缺乏系统评价和荟萃分析。因此，进行荟萃分析对于评估 HBO 治疗 UC 的疗效和安全性至关重要。
我们将制定一个系统检索计划，在以下七个数据库中进行检索，时间限制为从建库至 2020 年 9 月，以筛选合格的研究：PubMed、Web of Science、Embase、Cochrane 图书馆、中国知网、中文科技期刊数据库（维普）和中国生物医学文献数据库（万方）。还将搜索其他相关资源。两名独立评审员将选择合格的研究并提取数据。将基于 Cochrane 协作风险偏倚工具和 Newcastle-Ottawa 量表评估偏倚风险。最终，将使用 Review Manager V.5.3 统计软件和 STATA V.14.0 软件进行系统评价和荟萃分析。
本研究不涉及个体患者，也不存在任何伦理问题，因为其结果基于已发表的数据。因此，不需要伦理审查和批准。我们计划在同行评议的期刊上发表这项研究。
PROSPERO 注册号：CRD42020210244。
